Literature DB >> 34014333

Multidisciplinary care model for geriatric patients with hip fracture in Japan: 5-year experience.

Kenji Shigemoto1, Takeshi Sawaguchi2, Takeshi Horii3, Kenichi Goshima3, Shintaro Iwai3, Toshihiro Higashikawa4, Masashi Okuro4.   

Abstract

INTRODUCTION: Japan is a super-aging society, the geriatric care system establishment for hip fractures is at an urgent task. This report described our concept of multidisciplinary care model for geriatric hip fractures and 5-year outcomes at the Toyama City Hospital, Japan.
METHODS: In this retrospective cohort study, a multidisciplinary treatment approach was applied for elderly patients with hip fracture since 2014. These patients (n = 678, males: n = 143, mean age: 84.6 ± 7.5 years), were treated per the multidisciplinary care model. Time to surgery, length of hospital stays, complications, osteoporosis treatment, mortality, and medical costs were evaluated.
RESULTS: The mean time to surgery was 1.7 days. Overall, 78.0% patients underwent surgery within 2 days. The mean duration of hospital stay was 21.0 ± 12.4 days. The most frequent complication was deep venous thrombosis (19.0%) followed by dysuria (14.5%). Severe complications were pneumonia 3.4%, heart failure 0.8% and pulmonary embolism 0.4%. The in-hospital mortality rate was 1.2%. The 90-day, 6-month, and 1-year mortality rates were 2.5%, 6.7%, and 12.6%, respectively. The pharmacotherapy rate for osteoporosis at discharge was 90.7%, and the continuation pharmacotherapy rate was 84.7% at 1-year follow-up. The total hospitalization medical cost per person was lower than about 400 other hospitals' average costs every year, totaled 14% less during the 5-year study period.
CONCLUSION: We have organized a multidisciplinary team approach for geriatric hip fracture. This approach resulted in a shorter time to surgery and hospital stay than the national average. The incidence of severe complications and mortality was low. The multidisciplinary treatment has maintained a high rate of osteoporosis treatment after discharge and at follow-up. Furthermore, the total medical cost per person was less than the national average. Thus, the multidisciplinary treatment approach for geriatric hip fractures was effective and feasible to conduct in Japan.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Geriatric fractures; Hip fractures; Multidisciplinary care model; Orthogeriatric comanagement; Osteoporosis treatment; Secondary fracture prevention

Mesh:

Year:  2021        PMID: 34014333     DOI: 10.1007/s00402-021-03933-w

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   2.928


  3 in total

1.  An orthogeriatric collaborative intervention program for fragility fractures: a retrospective cohort study.

Authors:  Andraay Hon-Chi Leung; Tsz-Ping Lam; Wing-Hoi Cheung; Tan Chan; Pan-Ching Sze; Thomas Lau; Kwok-Sui Leung
Journal:  J Trauma       Date:  2011-11

2.  Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery.

Authors:  H W Thaler; R E Roller; N Greiner; E Sim; C Korninger
Journal:  J Trauma       Date:  2001-09

Review 3.  Fragility fracture prevention: review from a Japanese perspective.

Authors:  Hiroshi Hagino
Journal:  Yonago Acta Med       Date:  2012-06-30       Impact factor: 1.641

  3 in total
  2 in total

1.  Low serum calcium is associated with perioperative blood loss and transfusion rate in elderly patients with hip fracture: a retrospective study.

Authors:  Zhicong Wang; Xi Chen; Yan Chen; Ling Yang; Hong Wang; Wei Jiang; Shuping Liu; Yuehong Liu
Journal:  BMC Musculoskelet Disord       Date:  2021-12-07       Impact factor: 2.362

2.  A multicenter study of 1-year mortality and walking capacity after spinal fusion surgery for cervical fracture in elderly patients.

Authors:  Takeshi Sasagawa; Noriaki Yokogawa; Hiroyuki Hayashi; Hiroyuki Tsuchiya; Kei Ando; Hiroaki Nakashima; Naoki Segi; Kota Watanabe; Satoshi Nori; Kazuki Takeda; Takeo Furuya; Atsushi Yunde; Shota Ikegami; Masashi Uehara; Hidenori Suzuki; Yasuaki Imajo; Toru Funayama; Fumihiko Eto; Akihiro Yamaji; Ko Hashimoto; Yoshito Onoda; Kenichiro Kakutani; Yuji Kakiuchi; Nobuyuki Suzuki; Kenji Kato; Yoshinori Terashima; Ryosuke Hirota; Tomohiro Yamada; Tomohiko Hasegawa; Kenichi Kawaguchi; Yohei Haruta; Shoji Seki; Hitoshi Tonomura; Munehiro Sakata; Hiroshi Uei; Hirokatsu Sawada; Hiroyuki Tominaga; Hiroto Tokumoto; Takashi Kaito; Yoichi Iizuka; Eiji Takasawa; Yasushi Oshima; Hidetomi Terai; Koji Tamai; Bungo Otsuki; Masashi Miyazaki; Hideaki Nakajima; Kazuo Nakanishi; Kosuke Misaki; Gen Inoue; Katsuhito Kiyasu; Koji Akeda; Norihiko Takegami; Toshitaka Yoshii; Masayuki Ishihara; Seiji Okada; Yasuchika Aoki; Katsumi Harimaya; Hideki Murakami; Ken Ishii; Seiji Ohtori; Shiro Imagama; Satoshi Kato
Journal:  BMC Musculoskelet Disord       Date:  2022-08-20       Impact factor: 2.562

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.